Market Access Canada

Maximum Purchase:
1 unit
Publication Date:
September 2013
Adding to cart… The item has been added

Ten provinces. Three territories. Three layers of government. And pharmaceutical spending of C$33 billion a year.

Over the next five years, the International Monetary Fund estimates that Canada’s growth with steady at 4.2 percent, per year. Why? Along with a wealthy, educated population, Canada has also developed an intricate mosaic of relationships between Federal and provincial governments when it comes to healthcare. While drug approval is done at the Federal level, the organisation, management and funding of reimbursements comes under provincial power. What’s more, while prices for branded drugs are set at the national level, generics are managed by the provinces.

It’s a fragmented system that presents both challenges and opportunities for the pharmaceutical industry. In Market Access Canada, FirstWord explores the Canadian economic geography from coast to coast. The report examines the relationship between Federal and provincial government healthcare roles, the variation in provincial reimbursement models, and the size, structure and characteristics of the Canadian pharmaceutical market. Based on up-to-the-minute research, the report offers insight into the complexities of the Canadian pharma landscape.

Key Report Features of Market Access Canada include:

  • Detailed knowledge of the national and provincial pharmaceutical mandates
  • Insights into pricing, reimbursement and the role of health technology assessments
  • Discussion of different provincial approaches and their impact on equitable patient access
  • Examination of challenges and opportunities for both branded and generic drug markets
  • Insight into how prices are set and what methods are used to do so

Key Benefits

Although Canada’s is a complex, multi-tiered system, there are substantial opportunities for pharmaceutical companies with the right insight. Amongst the many benefits in Market Access Canada, this report will help you to:

  • Understand the scope and nature of the Canadian market
  • Learn the intricacies of national and provincial pricing measures and reimbursement policies
  • Understand patient access and drug shortfall issues caused by provincial reimbursement approaches and what the Federal government is doing to address them
  • Develop key knowledge about the specific challenges faced by biosimilars and biologics


Market Access Canada answers key questions:

  • Where are the best opportunities in Canada?
  • What is the best process for bringing new drugs to market?
  • What is the flow and process of drug approvals?
  • How have reforms to pricing and intellectual property altered the balance between branded and generic drugs?
  • How does Canada cooperate internationally and how does this feed back to the domestic market?

Key facts

  • The estimated total pharmaceutical market in Canada is C$33 billion, with C$20.6 billion of that from the private health insurance market.
  • Pharmaceutical expenditure represents 33 percent of private health care spending, compared to only 8.5 percent in the public health sector.
  • In 2012, overall growth was estimated at 3.3 percent: public drug spending has dropped from 7.9 percent in 2009 to 2.2 percent in 2010.
  • In 2012, provincial funding for prescription drugs hit C$10.6 billion or 86.6 percent of public pharma spending.

Content Highlights

Canada’s market is complex and varied. In this report, you will discover:

  • How drug reimbursement varies from province to province and what that means to pharma
  • The hidden cost to national policies caused by provincial reimbursement guidelines
  • The current state of regulations governing imported branded versus locally manufactured generics
  • The market prospects for branded and generic companies, and how pricing and intellectual property reforms will change the future competitive landscape
  • The specific challenges faced by new expensive drugs such as biologics, the likely effect of biosimilars on the market and how patients can get better access to orphan drugs.

Major chapters covering:

  • Market size and trends
  • Canada's drug approval process
  • Intellectual property in Canada
  • Canada's drug pricing system
  • Drug reimbursement and HTA
  • Biologics and orphan drugs
  • Where are Canada's drugs sourced from?
  • Drug distribution in Canada